Abstract
Background Both earlier and later age at menarche (AAM) are associated with increased risk of coronary artery disease (CAD) in women. This study sought to determine if the relationship of AAM with CAD and CAD risk factors differs for underlying sources of variation in AAM – specifically, variation attributable to common genetic variants as represented by a polygenic score (PGS) vs. variation independent of the PGS.
Methods Primary analyses were conducted on data from 201,037 women in the UK Biobank and validation studies on data from 23,268 women in the Women’s Genome Health Study (WGHS). For each individual, a PGS for AAM was calculated, then two variables were estimated from linear regression models: the PGS-associated change in AAM and the PGS-independent change in AAM. Logistic regression and linear splines were then used to study the relationships of these variables with CAD and CAD risk factors: hemoglobin A1c, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), systolic and diastolic blood pressure, body mass index, and waist-hip ratio.
Results PGS-associated change in AAM demonstrated a linear relationship with CAD and linear or roughly linear relationships with CAD risk factors. In contrast, PGS-independent change in AAM demonstrated a U-shaped relationship with CAD and with hemoglobin A1c, triglycerides, HDL-C, and waist-hip ratio. Validation studies using WGHS data produced similar results.
Conclusions These results suggest that later AAM itself does not cause increased risk of CAD; rather, upstream sources of variation other than common genetic variants can cause both later AAM and increased risk of CAD. Dysglycemia, dyslipidemia, and central adiposity are candidate mediators of the association of later AAM with increased risk of CAD.
Competing Interest Statement
Y.-M.C. receives royalties from UpToDate on topics related to puberty
Clinical Trial
Trial registration ID for Women's Health Study: NCT00000479
Funding Statement
A.S. was supported by National Institutes of Health (NIH) grant T32DK007699. The Women's Genome Health Study and its parent cohort, the Women?s Health Study (WHS), have been supported by the National Heart, Lung, and Blood Institute (HL043851 and HL080467) and the National Cancer Institute (CA047988 and UM1CA182913), with support and funding for genotyping provided by Amgen. Some cardiovascular endpoints in the WHS were funded by HL099355.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The two study cohorts used in these analyses received appropriate ethical approvals. The UK Biobank obtained the multiple ethical and regulatory approvals required for recruitment and research procedures, and participants provided written consent. The Women's Genome Health Study was approved by the institutional review board of Brigham and Women's Hospital, and participants consented to ongoing analyses.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available through the UK Biobank and Women?s Genome Health Study.
Non-standard Abbreviations and Acronyms: AAM: age at menarche
- BMI
- body-mass index
- CAD
- coronary artery disease
- DBP
- diastolic blood pressure
- HbA1c
- hemoglobin A1c
- HDL-C
- high-density lipoprotein cholesterol
- LDL-C
- low-density lipoprotein cholesterol
- PGS
- polygenic score
- SBP
- systolic blood pressure
- WGHS
- Women’s Genome Health Study
